Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 28,586,488
  • Shares Outstanding, K 224,560
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399,000 K
  • 36-Month Beta 1.39
  • Price/Sales 9.27
  • Price/Cash Flow 21.20
  • Price/Book 3.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.17 +10.79%
on 07/06/17
130.02 -0.16%
on 06/23/17
+10.76 (+9.04%)
since 06/20/17
3-Month
96.18 +34.97%
on 05/26/17
133.67 -2.89%
on 05/02/17
+11.09 (+9.34%)
since 04/20/17
52-Week
96.18 +34.97%
on 05/26/17
145.41 -10.73%
on 11/04/16
+2.88 (+2.27%)
since 07/20/16

Most Recent Stories

More News
Is a Beat in Store for Alexion (ALXN) this Earnings Season?

Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

AGEN : 5.03 (+3.07%)
GILD : 73.42 (+0.96%)
ICPT : 128.66 (+1.74%)
ALXN : 129.81 (+1.97%)
Is Gilead (GILD) Poised for a Beat This Earnings Season?

Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

VRTX : 159.33 (-0.23%)
ABBV : 74.01 (+1.70%)
GILD : 73.42 (+0.96%)
ALXN : 129.81 (+1.97%)
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

SRPT : 40.93 (+20.10%)
PBYI : 94.75 (-0.94%)
VRTX : 159.33 (-0.23%)
GILD : 73.42 (+0.96%)
AMGN : 179.32 (+0.08%)
ALXN : 129.81 (+1.97%)
BIIB : 281.44 (-0.18%)
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

ENZ : 11.47 (-1.12%)
ALIM : 1.58 (+3.95%)
CELG : 136.31 (+0.97%)
EXAS : 39.04 (-0.26%)
SRPT : 40.93 (+20.10%)
VRTX : 159.33 (-0.23%)
REGN : 521.13 (+2.83%)
KITE : 109.89 (+4.23%)
ALXN : 129.81 (+1.97%)
Alexion Reportedly Being Investigated by HHS, Shares Slip

Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS)...

ENZ : 11.47 (-1.12%)
AGEN : 5.03 (+3.07%)
ADRO : 13.70 (+1.86%)
ALXN : 129.81 (+1.97%)
Top Stock Reports for Oracle, Allergan & Abbott

Top Stock Reports for Oracle, Allergan & Abbott

ABT : 50.85 (+2.87%)
VLO : 67.52 (-0.75%)
AGN : 249.07 (+1.08%)
ADBE : 149.94 (+0.68%)
ORCL : 51.13 (+0.25%)
ALXN : 129.81 (+1.97%)
Alexion Receives Positive CHMP Opinion for Soliris(R) (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion...

ALXN : 129.81 (+1.97%)
Today's Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Alexion Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 21, 2017 / Regeneron's shares were down and then way up in yesterday's trading session. Shares dropped after Novartis released clinical trial data on an experimental drug...

NVS : 85.42 (+0.46%)
REGN : 521.13 (+2.83%)
ALXN : 129.81 (+1.97%)
Watch for Alexion Pharmaceuticals to Potentially Pullback After Gaining 3.16% Yesterday

Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $116.66 to a high of $120.75. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day...

ALXN : 129.81 (+1.97%)
BUYINS.NET: ALXN SqueezeTrigger Price is $119.60. There is $480,836,221 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in real time and just received an alert that ALXN is crossing above its primary SqueezeTrigger Price, the price that...

ALXN : 129.81 (+1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 131.69
1st Resistance Point 130.75
Last Price 129.81
1st Support Level 128.11
2nd Support Level 126.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.